UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies

Inflammatory bowel diseases, 2016-08, Vol.22 (8), p.1999-2015

2016

Volltextzugriff (PDF)

Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study

Annals of the rheumatic diseases, 2018-02, Vol.77 (2), p.228-233

2018

Volltextzugriff (PDF)

High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort

Annals of the rheumatic diseases, 2017-01, Vol.76 (1), p.208-213

2017

Volltextzugriff (PDF)

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA

Rheumatology (Oxford, England), 2017-09, Vol.56 (9), p.1498-1509

2017

Volltextzugriff (PDF)

Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development

Gastroenterology (New York, N.Y. 1943), 2018-09, Vol.155 (3), p.696-704

2018

Volltextzugriff (PDF)

Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol

Journal of rheumatology, 2015-12, Vol.42 (12), p.2270-2278

2015

Volltextzugriff (PDF)

Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials

Gastroenterology (New York, N.Y. 1943), 2022-02, Vol.162 (2), p.482-494

2022

Volltextzugriff (PDF)

Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study

Annals of the rheumatic diseases, 2017-11, Vol.76 (11), p.1890-1896

2017

Volltextzugriff (PDF)

Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial

Clinical cancer research, 2021-02, Vol.27 (4), p.1037-1047

2021

Volltextzugriff (PDF)

Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study

Modern rheumatology, 2017-11, Vol.27 (6), p.1031-1035

2017

Volltextzugriff (PDF)

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

The Lancet (British edition), 2016-12, Vol.388 (10061), p.2763-2774

2016

Volltextzugriff (PDF)

Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2016-08, Vol.10 (8), p.989-997

2016

Volltextzugriff (PDF)

Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials

Journal of the European Academy of Dermatology and Venereology, 2019-03, Vol.33 (3), p.546-552

2019

Volltextzugriff (PDF)

Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn’s disease

Alimentary pharmacology & therapeutics, 2020-06, Vol.51 (11), p.1031-1038

2020

Volltextzugriff (PDF)

Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases

International journal of molecular sciences, 2017-01, Vol.18 (1), p.228

2017

Volltextzugriff (PDF)

Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study

Inflammatory bowel diseases, 2016-08, Vol.22 (8), p.1870-1880

2016

Volltextzugriff (PDF)

Improvement of Certolizumab Fab′ properties by PASylation technology

Scientific reports, 2020-10, Vol.10 (1), p.18464, Article 18464

2020

Volltextzugriff (PDF)

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study

Annals of the rheumatic diseases, 2017-01, Vol.76 (1), p.96-104

2017

Volltextzugriff (PDF)

The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression

Annals of the rheumatic diseases, 2016-01, Vol.75 (1), p.75-83

2016

Volltextzugriff (PDF)

Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients

Joint, bone, spine : revue du rhumatisme, 2016-05, Vol.83 (3), p.341-343

2016

Volltextzugriff (PDF)

Biologic interventions for fatigue in rheumatoid arthritis

Cochrane database of systematic reviews, 2016-06, Vol.2016 (6), p.CD008334

2016

Volltextzugriff (PDF)

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

Journal of clinical pharmacology, 2015-08, Vol.55 (8), p.866-874

2015

Volltextzugriff (PDF)

A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients

Frontiers in immunology, 2020-05, Vol.11, p.845-845

2020

Volltextzugriff (PDF)

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation

Health technology assessment (Winchester, England), 2016-04, Vol.20 (35), p.1-610

2016

Volltextzugriff (PDF)

Certolizumab Pegol Does Not Bind the Neonatal Fc Receptor (FcRn): Consequences for FcRn-Mediated In Vitro Transcytosis and Ex Vivo Human Placental Transfer

Journal of reproductive immunology, 2016-08, Vol.116, p.7-12

2016

Volltextzugriff (PDF)

1 – 25 von 992

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(841)
Mit Volltextzugriff
(707)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

8 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(739)
Certolizumab Pegol
(730)
Life Sciences & Biomedicine
(725)
Humans
(711)
Female
(353)
Adalimumab
(344)
Tumor Necrosis Factor-Alpha - Antagonists & Inhibitors
(315)
Male
(278)
Infliximab
(275)
Treatment Outcome
(267)
Adult
(262)
Rheumatology
(259)
Rheumatoid Arthritis
(255)
Polyethylene Glycols - Therapeutic Use
(251)
Middle Aged
(242)
Immunoglobulin Fab Fragments - Therapeutic Use
(236)
Arthritis, Rheumatoid - Drug Therapy
(223)
Certolizumab Pegol - Therapeutic Use
(209)
Antibodies, Monoclonal - Therapeutic Use
(202)
Crohn Disease - Drug Therapy
(191)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(718)
Journals@OVID
(402)
EZB Electronic Journals Library
(365)
IngentaConnect
(340)
IngentaConnect Journals
(168)
Wiley Online Library All Journals
(163)
SpringerLink_现刊
(157)
Single Journals
(119)
Elsevier ScienceDirect Journals
(118)
Oxford journals
(111)
Taylor & Francis Journals
(110)
Wiley Online Library
(99)
Oxford Journals 2020 Medicine
(86)
Taylor & Francis
(86)
Nexis Uni
(81)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(65)
Taylor & Francis:Master (3349 titles)
(63)
BMJ journals (British Medical Journal and others)
(58)
BMJ Journals Archiv - DFG Nationallizenzen
(40)
Ebook Central Perpetual and DDA
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies

Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study

High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA

Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development

Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol

Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials

Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study

Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial

Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease

Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials

Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn’s disease

Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases

Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study

Improvement of Certolizumab Fab′ properties by PASylation technology

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study

The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression

Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients

Biologic interventions for fatigue in rheumatoid arthritis

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients

Certolizumab Pegol Does Not Bind the Neonatal Fc Receptor (FcRn): Consequences for FcRn-Mediated In Vitro Transcytosis and Ex Vivo Human Placental Transfer

Suchergebnisse filtern